Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 41-49

  Kim, Beom Kyung ^a   Han, Kwang Hyub ^a,b   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

Author keywords

Antiviral therapy; Chronic hepatitis B; HBV vaccine; Hepatocellular carcinoma; Prevention

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA INTERFERON; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2B; PREDNISOLONE; VIRUS DNA;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ECHOGRAPHY; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MEDICAL LITERATURE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; TUMOR RECURRENCE; VACCINATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; PRIMARY PREVENTION; SECONDARY PREVENTION; TERTIARY PREVENTION;

EID: 84855303449     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333258     Document Type: Review

References (72)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94153-156.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;3621907-1917.
3. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110129-137.
4. Han KH, Park JY: Systemic treatment in advanced/ metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;251023-1025.
5. Han KH, Ahn SH: How to predict HCC development in patients with chronic B viral liver disease? Intervirology 2005;4823-28.
6. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007;45507-539.
7. Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY, Kim YS, Park K, Kim DK, Moon YM: Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000;311371-1373.
8. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, Park JY, Myoung SM, Kim do Y, Chon CY, Han KH: MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008;291192-1196.
9. Liaw YF, Lin DY, Chen TJ, Chu CM: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989;9235-241.
10. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY: Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42:188-194. (Pubitemid 40143464)
11. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS: Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135796-800.
12. Chang MH: Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003;23309-314.
13. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children - Taiwan childhood hepatoma study group. N Engl J Med 1997;336:1855-1859.
14. Wichajarn K, Kosalaraksa P, Wiangnon S: Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008;9507-509.
15. Lanier AP, Holck P, Ehrsam Day G, Key C: Childhood cancer among Alaska natives. Pediatrics 2003;112:e396.
16. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections: the retrovirus epidemiology donor study. N Engl J Med 1996;3341685-1690.
17. Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2010;25:657-663.
18. Wang JT, Lee CZ, Chen PJ, Wang TH, Chen DS: Transfusion-transmitted HBV infection in an endemic area: the necessity of more sensitive screening for HBV carriers. Transfusion 2002;42:1592-1597.
19. Shang G, Seed CR, Wang F, Nie D, Farrugia A: Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007;47:529-539.
20. Dodd RY: Current viral risks of blood and blood products. Ann Med 2000;32:469-474.
21. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174. (Pubitemid 34764820)
22. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
23. Wu C, Yu M, Lin C, Liu C, Shih W, Tsai K, Chen C: Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008;29:106-112. (Pubitemid 351201748)
24. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45-52.
25. Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF: Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004;11:349-357.
26. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence- based approach. J Hepatol 2001;34:593-602. (Pubitemid 32328518)
27. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL: Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.
28. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
29. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL: Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
30. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2,795 patients. Hepatol Res 2005;32:173-184. (Pubitemid 41078655)
31. Lim SG, Mohammed R, Yuen MF, Kao JH: Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009;24:1352-1357.
32. Kim BK, Han KH, Park YN, Park MS, Kim KS, Choi JS, Moon BS, Chon CY, Moon YM, Ahn SH: Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol 2008;97:246-252.
33. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Bernardi M, Trevisani F: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006;101:524-532. (Pubitemid 43340928)
34. Zhang BH, Yang BH, Tang ZY: Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422.
35. Lin DY, Liaw YF: Optimal surveillance of hepatocellular carcinoma in patients with chronic viral hepatitis. J Gastroenterol Hepatol 2001;16:715-717.
36. Mok TS, Yeo W, Yu S, Lai P, Chan HL, Chan AT, Lau JW, Wong H, Leung N, Hui EP, Sung J, Koh J, Mo F, Zee B, Johnson PJ: An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha- fetoprotein levels or abdominal ultrasonography results. J Clin Oncol 2005;23:8041-8047. (Pubitemid 46657406)
37. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH: PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72(suppl 1):52-57.
38. Yoon YJ, Han KH, Kim do Y: Role of serum prothrombin induced by vitamin k absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Scand J Gastroenterol 2009;44:861-866.
39. Colombo M, Donato MF: Prevention of hepatocellular carcinoma. Semin Liver Dis 2005;25:155-161. (Pubitemid 40781068)
40. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-382.
41. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-842. (Pubitemid 46809282)
42. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465.
43. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554. (Pubitemid 44970357)
44. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232. (Pubitemid 30614654)
45. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299-306. (Pubitemid 36205926)
46. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-422. (Pubitemid 34595504)
47. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma: a randomized, controlled trial. Ann Intern Med 2001;134:963-967. (Pubitemid 32466235)
48. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975-981.
49. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL: Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-894.
50. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S: Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437-448. (Pubitemid 36432418)
51. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000;32:43-48. (Pubitemid 30432364)
52. Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M: The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol 2009;44:991-999.
53. Kubo S, Hirohashi K, Yamazaki O, Matsuyama M, Tanaka H, Horii K, Shuto T, Yamamoto T, Kawai S, Wakasa K, Nishiguchi S, Kinoshita H: Effect of the presence of hepatitis B e antigen on prognosis after liver resection for hepatocellular carcinoma in patients with chronic hepatitis B. World J Surg 2002;26:555-560. (Pubitemid 36920366)
54. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF: Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008;103:1663-1673.
55. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY: Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-897.
56. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu XD, Fan J, Tang ZY: Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007;47:684-690. (Pubitemid 47503431)
57. Ohkubo K, Kato Y, Ichikawa T, Kajiya Y, Takeda Y, Higashi S, Hamasaki K, Nakao K, Nakata K, Eguchi K: Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002;94:2663-2668. (Pubitemid 34478081)
58. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111. (Pubitemid 44202603)
59. Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH: Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008;28:393-401. (Pubitemid 351279588)
60. Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Sakaguchi H, Tamori A, Habu D, Nishiguchi S: Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007;37:94-100. (Pubitemid 46403823)
61. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa - European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997;26:1338-1342. (Pubitemid 27509322)
62. Brunetto MR, Oliveri F, Koehler M, Zahm F, Bonino F: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study -International Interferon-Alpha Hepatocellular Carcinoma Study Group. Lancet 1998;351:1535-1539. (Pubitemid 28230887)
63. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A: Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-909. (Pubitemid 28401923)
64. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, Kumada H: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827-835. (Pubitemid 28104160)
65. Krogsgaard K: The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B: the Long-Term Follow-Up Investigator Group - the European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-397.
66. Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferonalpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34:306-313. (Pubitemid 32176454)
67. Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P: Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 2001;32:452-458. (Pubitemid 33701572)
68. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-145. (Pubitemid 32591494)
69. Truong BX, Seo Y, Kato M, Hamano K, Ninomiya T, Katayama M, Kato H, Yano Y, Hayashi Y, Kasuga M: Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005;16:279-284.
70. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-147.
71. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t) ide analog therapy starting with lamivudine. Hepatology 2005;42:121-129. (Pubitemid 40911319)
72. Eun JR, Lee HJ, Lee SH: The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in hepatitis B virus-related liver cirrhosis. Hepatology 2007;46:664A-665A.